Table 1 Characteristics of included studies
Study | Year | Country | No. | Cancer type | Design | Follow-up | Cut-off | Outcome | Treatment | HR source | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|
Huang [14] | 2019 | China | 458 (328 [training] + 130 [validation])a | Cervical cancer (FIGO stage I, II) | R, multi-center | 47 m | 475 | OS, LNM, LVI | Surgery | M | 9 |
Nie [11] | 2019 | China | 533 (250 [training] + 283 [validation])a | Ovarian cancer (FIGO stage I-IV) | R, multi-center | 46 m | 612 | OS, PFS, LNM | Surgery | M | 9 |
Farolfi [15] | 2018 | Italy | 375 | Ovarian cancer (FIGO stage III-IV) | R, multi-center | 43 m | 730 | OS, PFS | Chemotherapy | M | 7 |
De Giorgi [16] | 2019 | USA | 516 | Breast cancer (triple-negative, HER2+, HER2– ER+) | R, single-center | – | 836 | OS | Systemic treatment | Overall (U), subtype (M) | 8 |
Liu [12] | 2019 | China | 160 | Triple-negative breast cancer | R, single-center | 61.7 m | 557 | OS, DFS | Surgery, chemotherapy, radiotherapy | M | 8 |
Sun [21] | 2019 | China | 155 | Hormone receptor-HER2 + breast cancer | R, single-center | 57.6 m | 578 | OS, DFS, LNM | Surgery, chemotherapy, radiotherapy | M | 9 |
Li [22] | 2019 | China | 161 | Luminal breast cancer | R, single-center | 28.4 m | 518 | DFS, LNM, LVI | Surgery, chemotherapy, radiotherapy, endocrine therapy | M | 9 |
Wang [13] | 2019 | China | 215 | Triple-negative breast cancer | R, single-center | 49.2 m | 624 | OS, DFS, LNM | Surgery, chemotherapy, radiotherapy | M | 9 |
Holub [20] | 2019 | Spain | 151 | Cervical cancer (FIGO stages I–IV) | R, single-center | 43.8 m | 1000 | OS | Surgery, chemotherapy, radiotherapy | U | 9 |